^
    Back
    Association details:
    Biomarker:ROS1 G2032R
    Cancer:Non Small Cell Lung Cancer
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    ESMO 2020
    Title:

    1368P - Lorlatinib in pretreated ALK/ROS1-positive non-small cell lung cancer (NSCLC): Results from the German early access program

    Published date:
    09/14/2020
    Excerpt:
    Patients with documented treatment failure of all approved ALK/ROS1-specific therapies (or with resistance mutations not covered by approved inhibitors or with leptomeningeal disease) and at least one other systemic treatment for metastatic NSCLC...Median duration of treatment with lorlatinib was 10.6 months (6.5-12.8)...G1202R/G2032R conferred a reduced PFS (4.1 vs. 11.0 months, p=0.04)...
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Curr Oncol
    Title:

    Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy

    Published date:
    09/16/2022
    Excerpt:
    ...we report a ROS1+ NSCLC patient who developed an on target G2032R resistance mutation during second-line lorlatinib treatment, indicating the lack of activity of lorlatinib against ROS1 G2032R.
    DOI:
    10.3390/curroncol29090520